Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723243 | 0.86 | LMNA (0.44) | METAXLRXFP1LMNATP53 | |
| SCHEMBL199584 | 0.84 | NOTUM (0.39) | METAXLLMNAKDM4EPOLB | |
| SCHEMBL22249472 | 0.82 | THRB (0.41) | METAXLRXFP1LMNATP53 | |
| SCHEMBL22249789 | 0.81 | MEN1 (0.49) | METAXLRXFP1LMNATP53 | |
| SCHEMBL23749505 | 0.78 | MET (0.48) | METAXLRXFP1LMNATP53 | |
| SCHEMBL3831757 | 0.78 | MET (0.39) | METAXLRXFP1LMNATP53 | |
| SCHEMBL2592272 | 0.75 | MET (0.51) | METAXLKDM4EMAPT | |
| SCHEMBL3715544 | 0.73 | ALDH1A1 (0.39) | METAXLRXFP1LMNATP53 | |
| SCHEMBL2477308 | 0.72 | LMNA (0.46) | METAXLRXFP1LMNATP53 | |
| SCHEMBL201513 | 0.71 | NOTUM (0.45) | METAXLLMNAKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595273-B2 | Phosphonate conjugates and uses thereof | TRANSLATIONAL GENOMICS RES INST (US) | 2026-04-07 | — | — | US | disclosed |
| US-20220119425-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | UNITED STATES GOVERNMENT | 2022-04-21 | — | — | US | disclosed |
| EP-3911320-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | The Translational Genomics Research Institute (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150307-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150307-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20180148447-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | IGNYTA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-3309160-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | Ignyta, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9914731-B2 | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | IGNYTA, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| EP-3087070-B1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | IGNYTA INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160318929-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | CEPHALON, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9387202-B2 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-07-12 | — | — | US | disclosed |
| WO-2015100117-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | CEPHALON, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20150148380-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2015-05-28 | — | — | US | disclosed |
| US-9012635-B2 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-8921565-B2 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140343103-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2782577-A2 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, LLC. (US) | 2014-10-01 | — | — | EP | disclosed |
| WO-2014145004-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20130317066-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2013078295-A2 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148380-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | MKI67, TYMP, CCNA1 | MET 2197/4885AXL 3090/4885RXFP1 3696/4885 |
| US-20130317066-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | MKI67, TYMP, CCNA1 | MET 2197/4885AXL 3090/4885RXFP1 3696/4885 |
| US-20180148447-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | AXL, FLT3, ERBB2 | MET 10/4885AXL 1/4885RXFP1 1209/4885 |
| US-20220119425-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | ACP1, PTMS, RET | MET 53/4885AXL 97/4885RXFP1 601/4885 |
| US-12595273-B2 | Phosphonate conjugates and uses thereof | RET, PTK2, ERBB2 | MET 46/4885AXL 78/4885RXFP1 354/4885 |
| US-20140343103-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | MKI67, TYMP, CCNA1 | MET 2197/4885AXL 3090/4885RXFP1 3696/4885 |
| US-20160318929-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | AXL, FLT3, ERBB2 | MET 10/4885AXL 1/4885RXFP1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.